esophageal
No description yet: the sentence for this tag has not been written. 5 records carry it: 5 people.
5 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
J. Jan B. van Lanschot Emeritus Professor of Surgery, Erasmus MC · Erasmus MC Cancer Institute Surgeon who led the CROSS trial, which made chemoradiotherapy before surgery the standard for oesophageal cancer. | Oesophageal cancer | none | surgery, chemoradiotherapy | ||
Jaffer A. Ajani Professor of Gastrointestinal Medical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Gastro-oesophageal oncologist who co-led CheckMate 649, the trial that added nivolumab to first-line gastric cancer chemotherapy. | Gastric & gastro-oesophageal junction cancer, Oesophageal cancer | none | gastric, immunotherapy | ||
Ken Kato Chief, Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo · National Cancer Center Hospital Japanese oncologist who led ATTRACTION-3 and KEYNOTE-590, bringing immunotherapy to oesophageal cancer. | Oesophageal cancer, Head and neck squamous cell carcinoma | none | immunotherapy, japan | ||
Rebecca C. Fitzgerald Director, Early Cancer Institute, University of Cambridge; Professor of Cancer Prevention · Cancer Research UK Cambridge Centre / CRUK Cambridge Institute Invented the Cytosponge, a swallowable sponge-on-a-string that finds Barrett's oesophagus without endoscopy. | Oesophageal cancer | none | early-detection, uk | ||
Ronan J. Kelly Director, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas · Charles A. Sammons Cancer Center, Baylor University Medical Center Led CheckMate 577, the first trial to show adjuvant immunotherapy helps oesophageal cancer patients with residual disease. | Oesophageal cancer, Gastric & gastro-oesophageal junction cancer | none | immunotherapy, adjuvant |